WO2012131412A3 - Pharmaceutical composition containing no, process for the preparation and use thereof - Google Patents

Pharmaceutical composition containing no, process for the preparation and use thereof Download PDF

Info

Publication number
WO2012131412A3
WO2012131412A3 PCT/HU2012/000023 HU2012000023W WO2012131412A3 WO 2012131412 A3 WO2012131412 A3 WO 2012131412A3 HU 2012000023 W HU2012000023 W HU 2012000023W WO 2012131412 A3 WO2012131412 A3 WO 2012131412A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
preparation
composition containing
relates
lipophil
Prior art date
Application number
PCT/HU2012/000023
Other languages
French (fr)
Other versions
WO2012131412A2 (en
Inventor
László Gábor SZABÓ
István Piller
Original Assignee
Szabo Laszlo Gabor
Piller Istvan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Szabo Laszlo Gabor, Piller Istvan filed Critical Szabo Laszlo Gabor
Priority to EP12725876.2A priority Critical patent/EP2691087A2/en
Publication of WO2012131412A2 publication Critical patent/WO2012131412A2/en
Publication of WO2012131412A3 publication Critical patent/WO2012131412A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The invention relates to a pharmaceutical composition comprising NO, wherein the composition comprises as NO-source a zeolite-free transition metal complex, preferably a ferrous-nitroso-sulphate, furthermore one or more lipophil carrier(s) and optionally one or more pharmaceutically acceptable excipient(s). The invention further relates to the process for the preparation of the above-mentioned pharmaceutical composition, and the use thereof as a medicine.˙
PCT/HU2012/000023 2011-03-31 2012-03-30 Pharmaceutical composition containing no, process for the preparation and use thereof WO2012131412A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12725876.2A EP2691087A2 (en) 2011-03-31 2012-03-30 Pharmaceutical composition containing no, process for the preparation and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1100176 2011-03-31
HUP1100176 2011-03-31

Publications (2)

Publication Number Publication Date
WO2012131412A2 WO2012131412A2 (en) 2012-10-04
WO2012131412A3 true WO2012131412A3 (en) 2012-12-13

Family

ID=89621381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2012/000023 WO2012131412A2 (en) 2011-03-31 2012-03-30 Pharmaceutical composition containing no, process for the preparation and use thereof

Country Status (2)

Country Link
EP (1) EP2691087A2 (en)
WO (1) WO2012131412A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860621A4 (en) * 2018-10-05 2022-07-06 Ampersand Biopharmaceuticals, Inc. Iron formulations for topical administration and methods of treatment of iron deficiency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018966A1 (en) * 1993-02-26 1994-09-01 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system with active substances which represent sources of nitrogen oxide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
ES2215027T3 (en) 1999-03-10 2004-10-01 Biora Bioex Ab COMPOSITIONS OF PROTEINS OF MATRICES DESTINED TO INDUCE APOPTOSIS.
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
GB0021317D0 (en) 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
BRPI0412273B1 (en) 2003-07-03 2019-09-24 The University Court Of The University Of St. Andrews PHARMACEUTICAL PREPARATION, USE OF A ZEOLITE MATERIAL, MEDICAL ARTICLE, COSMETIC PRODUCT AND / OR PERSONAL HYGIENE, AND NITRIC OXIDE RELEASE METHOD
EP1690554A1 (en) 2005-02-11 2006-08-16 NOLabs AB Device for treatment of infections, including dermatophytosis and onychomycosis
EP1757278A1 (en) 2005-08-23 2007-02-28 NOLabs AB Device, system, and method comprising microencapsulated liquid for release of nitric oxide from a polymer
WO2006097349A1 (en) 2005-03-15 2006-09-21 L'oreal Cosmetic use of a microporous solid crystalline material no for improving the natural colouring and/or appearance of the skin and/or lips
WO2006097351A1 (en) 2005-03-15 2006-09-21 L'oreal Anhydrous cosmetic composition comprising nitrogen monoxide in a microporous solid crystalline material
WO2006097352A1 (en) 2005-03-15 2006-09-21 L'oreal Cosmetic composition containing nitrogen monoxide in a microporous crystalline solid material
GB0616350D0 (en) 2006-08-17 2006-09-27 Univ St Andrews Adsorption and release of nitric oxide in metal organic frameworks

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018966A1 (en) * 1993-02-26 1994-09-01 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system with active substances which represent sources of nitrogen oxide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHRISTINA JÄGRÉN ET AL: "Skin microvascular dilatation response to acetylcholine and sodium nitroprusside in peripheral arterial disease", CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, vol. 22, no. 6, November 2002 (2002-11-01), pages 370 - 374, XP055038784, ISSN: 1475-0961, DOI: 10.1046/j.1475-097X.2002.00436.x *
EROY-REVELES A A ET AL: "Nitric oxide-donating materials and their potential in pharmacological applications for site-specific nitric oxide delivery", FUTURE MEDICINAL CHEMISTRY, FUTURE SCIENCE LTD, GB, vol. 1, no. 8, November 2009 (2009-11-01), pages 1497 - 1507, XP009162990, ISSN: 1756-8919, DOI: 10.4155/FMC.09.111 *
JI B Q ET AL: "Study on transdermal sodium nitroprusside delivery system", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 28, no. 1-3, 1 January 1994 (1994-01-01), pages 279 - 281, XP025526680, ISSN: 0168-3659, [retrieved on 19940101], DOI: 10.1016/0168-3659(94)90180-5 *
SEUNG NAMKOONG ET AL: "Therapeutic Application of Nitric Oxide in Human Diseases", BIOMOLECULES AND THERAPEUTICS, vol. 18, no. 4, 31 October 2010 (2010-10-31), pages 351 - 362, XP055038842, ISSN: 1976-9148, DOI: 10.4062/biomolther.2010.18.4.351 *
VANIN ET AL: "Dinitrosyl iron complexes with thiolate ligands: Physico-chemistry, biochemistry and physiology", NITRIC OXIDE: BIOLOGY AND CHEMISTRY, ACADEMIC PRESS, AMSTERDAM, NL, vol. 21, no. 1, 1 August 2009 (2009-08-01), pages 1 - 13, XP026284010, ISSN: 1089-8603, [retrieved on 20090412], DOI: 10.1016/J.NIOX.2009.03.005 *

Also Published As

Publication number Publication date
EP2691087A2 (en) 2014-02-05
WO2012131412A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
WO2010092090A3 (en) Novel salts of sitagliptin
WO2012021715A3 (en) Stable formulations of linaclotide
WO2014064410A3 (en) Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane
EP2415749A4 (en) New salvianolic acid compound l, preparation method and use thereof
WO2013179300A3 (en) A process for the preparation of vildagliptin and its intermediate thereof
SG10201804817TA (en) Delayed release compositions of linaclotide
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2013147649A3 (en) Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases
WO2013055684A8 (en) Rasagiline citramide
WO2013055689A8 (en) R(+)-n-methyl-propargyl-aminoindan
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2011089126A3 (en) Novel retigabine composition
IN2015DN00280A (en)
WO2013007361A8 (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
WO2012155226A8 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
WO2012122451A3 (en) Polymorphs of maxacalcitol and process for the preparation of maxacalcitol
WO2012019428A8 (en) Benzohydrol derivatives, a preparation process and pharmaceutical use thereof
WO2012131412A3 (en) Pharmaceutical composition containing no, process for the preparation and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12725876

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012725876

Country of ref document: EP